Foghorn Therapeutics (FHTX) filed an 8-K on November 5, 2025, detailing Q3 financial results and executive changes. The company remains focused on precision therapeutics using its Gene Traffic Control Platform®, primarily in oncology.
Financial & Liquidity Status: As of September 30, 2025, the company held $180.3M in cash, providing an expected runway into 2028. For Q3 2025, collaboration revenue was $8.2M, and the Net Loss narrowed year-over-year to $15.8M (from $19.1M).
Management Transition: CFO Kristian Humer resigned effective November 14, 2025, to pursue other opportunities
...